The WCM IRB is an appropriately constituted group whose primary responsibility is to ensure that the rights and welfare of human subjects in research are protected. In doing so, the IRB must ensure all human subject research activities is conducted ethically, and in compliance with Federal regulations, the requirements of applicable New York State and local law, and institutional policies and procedures.
We are pleased to announce a new partnership between the Weill Cornell Medicine IRB and the BRANY IRB, beginning on Monday, December 6, 2021: BRANYplus. Visit the BRANYplus site for more information.
The Weill Cornell Medicine Data and Safety Monitoring Committee (WCM DSMC) is an independent committee within the institution that is available to the research community to act as a monitoring entity for clinical trial.
The Human Research Routine Review & Education Program is a joint collaboration between Human Research Compliance and the Joint Clinical Trials Office Quality Assurance Unit (JCTO QAU). Through routine review and educational initiatives, the program intends to provide reasonable assurance of the integrity of all human research, improve human research protections, and identify quality improvement areas.
All WCMC investigators who intend to perform research involving human embryonic stem cells must submit notification to the Tri-Institutional ESCRO Committee. This requirement applies to all HESC research, regardless of the funding sources.
As part of the WCM Human Research Protections Program, the ClinicalTrials.gov program aims to provide researchers with assistance in fulfilling the scientific, regulatory, and ethical responsibilities associated with publicly registering and posting trial results on ClinicalTrials.gov.
The Weill Cornell Medicine Radiation Safety Committee (RSC) authorizes and oversees the possession, use, and disposal of all radioactive material used for research, clinical, instructional, and service purposes within Weill Cornell Medicine - NewYork Presbyterian Hospital Center.
The Weill Cornell Medicine Institutional Biosafety Committee (IBC) is a faculty-led committee of experts in biosafety-related fields established under the NIH Guidelines. The IBC ensures that all research conducted at Weill Cornell Medicine (WCM) complies with applicable Federal, State and local health, safety standards and Institutional policies.
The Weill Cornell Medicine-Qatar (WCM-Q) Institutional Review Board (IRB) will be responsible for reviewing all IRB protocols involving recruitment of subjects and study interventions occurring at WCM-Q.
The Health Insurance Portability and Accountability Act of 1996 (HIPAA) has special requirements that WCM researchers must follow when viewing or handling the protected health information ("PHI") of patients or other individuals for research purposes. These research provisions, as dictated by the HIPAA Privacy Rule and HIPAA Security Rule, are explained in the guide below.